# Immunoassay Market

> Immunoassay Market Research Report: Size, Share, Trend Analysis By Types (Enzyme-Linked Immunosorbent Assay, Radioimmunoassay, Fluorescent Immunoassay, Chemiluminescent Immunoassay, Western Blot), By Technology (Automated Immunoassay, Point of Care Immunoassay, Lateral Flow Assay), By Applications (Clinical Diagnostics, Drug Development, Environmental Testing, Food Safety Testing), By End Use (Hospitals, Diagnostic Laboratories, Pharmaceutical Companies, Academic Research Institutions) and By Region (North America, Europe, South America, Asia Pacific, Middle East and Africa) - Growth Outlook & Industry Forecast 2025 To 2035

- **Forecast Period:** 2025 - 2035
- **CAGR:** 3.86%
- **2024:** $ 25.25 Billion
- **2025:** $ 26.22 Billion
- **2035:** $ 38.3 Billion
- **Key Players:** Companies such as Abbott Laboratories (US), Roche Diagnostics (CH), Siemens Healthineers (DE), Thermo Fisher Scientific (US), Ortho Clinical Diagnostics (US), Bio-Rad Laboratories (US), Danaher Corporation (US), PerkinElmer (US), Fujirebio (JP) are some of the major participants in the global market.

**Report ID:** MRFR/HC/4385-HCR · **Pages:** 200 · **Author:** Vikita Thakur & Rahul Gotadki · **Last Updated:** July 22, 2026

**URL:** https://www.marketresearchfuture.com/reports/immunoassay-market-5841

---

## Market Summary

The Global Immunoassay Market size was valued at USD 25.25 Billion in 2024, and the market is projected to grow from USD 26.22 Billion in 2025 to USD 38.3 Billion by 2035, registering a CAGR of 3.8% during the forecast period 2025–2035. North America led the market in 2024 with over 45.15% share, generating around USD 10.6 Billion in revenue.
 
The Immunoassay Market is expanding due to increasing demand for rapid and accurate diagnostic testing in clinical and research settings. Key trends include advancements in ELISA and lateral flow assay technologies, growing adoption of automated immunoassay platforms, and rising applications in disease detection, drug development, and personalized medicine globally.
 
According to the WHO Data Portal, noncommunicable diseases account for approximately 74% of all deaths globally, highlighting the growing need for effective diagnostic tools. Immunoassay-based testing plays a crucial role in early disease detection and monitoring, supporting healthcare systems in managing the increasing global burden of chronic health conditions.

## Market Drivers

### Advancements in Immunoassay Technologies

Technological innovations in immunoassay methodologies are significantly influencing the Immunoassay Industry. The introduction of novel platforms, such as microfluidics and multiplex assays, enhances the efficiency and accuracy of diagnostic testing. These advancements allow for the simultaneous detection of multiple analytes, thereby streamlining the testing process and reducing turnaround times.
 
Furthermore, the integration of automation and [artificial intelligence](https://www.marketresearchfuture.com/reports/artificial-intelligence-market-1139) in immunoassay systems is expected to improve operational efficiency in laboratories. As a result, the market is projected to expand, with an estimated growth rate of over 8% annually in the coming years. This technological evolution not only meets the increasing demand for rapid diagnostics but also positions the market at the forefront of modern healthcare solutions.
 

- Technological advancements are strengthening the market by improving diagnostic accuracy and testing efficiency. According to PubMed research databases, multiplex immunoassay technologies enable simultaneous detection of multiple biomarkers in a single test, improving clinical workflow and supporting advanced disease profiling. These innovations are accelerating adoption across research and diagnostic applications.

### Increasing Prevalence of Chronic Diseases

The rising incidence of chronic diseases such as diabetes, cardiovascular disorders, and infectious diseases is a primary driver for the Immunoassay Industry. As healthcare systems strive to manage these conditions effectively, the demand for accurate and rapid diagnostic tools has surged. According to recent data, chronic diseases account for approximately 70% of all deaths worldwide, necessitating the need for reliable testing methods.
 
Immunoassays, known for their sensitivity and specificity, are increasingly utilized in clinical laboratories and point-of-care settings. This trend is expected to continue, as healthcare providers seek to enhance patient outcomes through timely diagnosis and monitoring. Consequently, the market is likely to experience substantial growth as it adapts to the evolving healthcare landscape.
 

- The increasing prevalence of chronic diseases is driving demand for reliable immunoassay-based diagnostics. According to IHME estimates, cardiovascular diseases remain the leading cause of global mortality, accounting for approximately 19.8 million deaths annually in 2022. This rising disease burden encourages wider adoption of immunoassays for early detection and continuous monitoring.

### Growing Awareness of Preventive Healthcare

The increasing emphasis on preventive healthcare is driving the Immunoassay Industry. As individuals become more health-conscious, there is a heightened demand for early detection and monitoring of diseases. Immunoassays play a crucial role in preventive healthcare by enabling timely diagnosis and facilitating proactive management of health conditions.
 
Market Research Future indicates that preventive healthcare spending is projected to rise significantly, reflecting a shift in focus from reactive to proactive health management. This trend is likely to bolster the demand for immunoassay tests, as healthcare providers and patients alike recognize the value of early intervention. Consequently, the market is poised for growth as it aligns with the broader movement towards preventive health strategies.

### Rising Demand for Home Healthcare Solutions

The growing preference for home healthcare solutions is reshaping the Immunoassay Industry. Patients increasingly seek convenient and accessible testing options that can be performed in the comfort of their homes. This trend is driven by a desire for personalized care and the need to reduce hospital visits. The market tests that are designed for home use, such as rapid tests for pregnancy and infectious diseases, are gaining traction. 
 
Market data indicates that the home healthcare segment is expected to witness a compound annual growth rate of approximately 10% over the next few years. This shift towards home-based testing not only enhances patient engagement but also drives innovation within the market, as manufacturers develop user-friendly and reliable testing kits.

### Regulatory Support for Diagnostic Innovations

Regulatory bodies are increasingly supporting innovations in diagnostic testing, which is positively impacting the Immunoassay Industry. Streamlined approval processes for new immunoassay technologies facilitate quicker market entry for novel products. This regulatory environment encourages research and development, leading to the introduction of advanced diagnostic solutions.
 
For instance, recent initiatives aimed at expediting the approval of point-of-care tests have opened new avenues for growth within the market. As a result, the market is likely to benefit from enhanced product offerings and increased competition, ultimately leading to improved patient care and outcomes. The proactive stance of regulatory agencies is expected to sustain the momentum of innovation in the immunoassay sector.

## Future Outlook

The Immunoassay Market size is projected to reach USD 38.3 Billion by 2035, growing at a CAGR of 3.8%, driven by technological advancements, increasing demand for rapid immunoassay diagnostics, and expanding applications in personalized medicine.

**New opportunities:**

- Development of point-of-care testing devices for remote diagnostics. Integration of AI in immunoassay data analysis for enhanced accuracy. Expansion into emerging markets with tailored immunoassay solutions.

By 2035, the Immunoassay Market is expected to achieve substantial growth, reflecting evolving healthcare needs.

## Segment Insights

### By Type: Chemiluminescent Immunoassay (Largest) vs. Enzyme-Linked Immunosorbent Assay (Fastest-Growing)

The Immunoassay Market is characterized by diverse methodologies, with the Chemiluminescent Immunoassay (CLIA) segment leading in market share due to its broad application in immunoassay diagnostics and increased sensitivity. Enzyme-Linked Immunosorbent Assay (ELISA) is gaining momentum as a vital tool in research and clinical settings, showcased by its substantial growth rate. Collectively, these methods cater to various therapeutic areas, including infectious diseases, hormone levels, and cancer detection, solidifying their integral roles in the healthcare realm. As the demand for efficient and precise diagnostic tools escalates, innovative technologies in Chemiluminescent Immunoassays continue to evolve, driving their dominance. Conversely, the emerging ELISA techniques are witnessing rapid advancements due to their cost-effectiveness and stellar reliability, enabling their penetration into new markets. Market players are focusing on enhancing assay performance and developing kits that cater to a broader range of diseases, prompting companies to capitalize on emerging trends and advancements to meet evolving customer needs.

Ortho Clinical Diagnostics has strengthened chemiluminescent immunoassay adoption through advanced diagnostic platforms. Its Vitros XT 7600 Integrated System combines multiple testing technologies, including immunodiagnostics, enabling laboratories to improve efficiency and workflow. The company’s innovations support high-quality clinical testing, enhancing the role of chemiluminescent immunoassays in modern diagnostic environments.

### By Technology: Automated Immunoassay (Largest) vs. Point of Care Immunoassay (Fastest-Growing)

The Immunoassay Market is segmented primarily into Automated Immunoassay, Point of Care Immunoassay, and Lateral Flow Assay. Among these, the Automated Immunoassay segment holds the largest share due to its widespread adoption in laboratories and diagnostic settings. With its high throughput and efficiency, Automated Immunoassays provide consistent results that are crucial for laboratory immunoassay diagnostics. Meanwhile, the Point of Care Immunoassay segment is rapidly gaining traction, driven by rising demand for rapid testing solutions in various healthcare settings, making it the fastest-growing segment in this market.

Bio-Rad Laboratories continues advancing automated immunoassay solutions through innovative diagnostic platforms and laboratory automation. Its quality control and diagnostic technologies support laboratories worldwide with improved accuracy and efficiency. The company serves healthcare markets across more than 100 countries, strengthening the adoption of automated diagnostic workflows and supporting the growing demand for high-throughput immunoassay testing.

### By Application: Clinical Diagnostics (Largest) vs. Drug Development (Fastest-Growing)

The market is segmented into Clinical Diagnostics, [Drug Development](https://www.marketresearchfuture.com/reports/drug-development-market-66529), Environmental Testing, and Food Safety Testing. Clinical Diagnostics holds the largest Immunoassay Market share, driven by the rising prevalence of chronic diseases. Drug Development is notable for its rapid growth as pharmaceutical companies increasingly rely on immunoassays for the development of new therapeutics. Environmental Testing and Food Safety Testing are also significant, but their shares are smaller in comparison, reflecting a more niche application of immunoassays primarily focused on regulatory compliance and safety assurance. Growth trends within this segment are favorable, with Clinical Diagnostics continuing to be propelled by technological advancements and the increasing demand for point-of-care testing. Drug Development is witnessing the fastest growth due to heightened investment in pharmaceuticals and biotechnologies seeking efficiency in drug discovery processes. Overall, the application of immunoassays in these sectors is expanding, indicating a robust overall growth trajectory for the market during the coming years.

Danaher Corporation supports clinical diagnostics growth through its advanced diagnostic businesses, including Beckman Coulter Diagnostics. The company provides automated immunoassay systems used in hospitals and laboratories globally. Beckman Coulter’s DxI series analyzers offer high-performance immunoassay testing capabilities, supporting faster diagnosis and improved clinical decision-making across healthcare settings.

### By End Use: Hospitals (Largest) vs. Diagnostic Laboratories (Fastest-Growing)

By end use, with hospitals being the largest contributor. This segment holds a significant Immunoassay Market share due to the high volume of diagnostic tests performed in healthcare settings. Hospitals leverage immunoassay tests for a variety of clinical applications, including disease diagnosis and monitoring, which sustains their leading position in this market. In contrast, diagnostic laboratories are emerging as a rapidly growing segment, primarily driven by the increasing demand for specialized diagnostic services and innovations in testing methods.

PerkinElmer enhances hospital-based immunoassay applications through advanced diagnostic technologies supporting disease screening and monitoring. The company’s neonatal screening solutions have tested millions of newborns globally, demonstrating the importance of early diagnostics. Its innovative platforms help hospitals improve patient outcomes through accurate and efficient immunoassay-based testing solutions.

## Regional Market Share Analysis

North America leads in the Immunoassay Market Size, accounting for over 41.98% of the global revenue in 2024, showcasing its majority holding in the [therapeutic drug monitoring](https://www.marketresearchfuture.com/reports/therapeutic-drug-monitoring-market-42591) market due to advanced healthcare infrastructure and high adoption of immunoassay techniques. Europe follows closely, with a valuation of 8.2 USD Billion in 2024, projected to rise to 12.5 USD Billion, driven by an increasing focus on healthcare research and innovation.

Europe market size was valued at USD 8.2 Billion in 2024, making it the second-largest regional market with a 32.48% share, regional governments prioritize improving healthcare access and diagnostics. South America, valued at 1.7 USD Billion, is expected to grow to 2.4 USD Billion, highlighting emerging trends in healthcare investment.

- Thermo Fisher Scientific continues strengthening the European market through advanced diagnostic solutions and collaborations. The company supports healthcare research and clinical laboratories with innovative immunoassay platforms, including automated analyzers and specialized testing solutions. According to the European Medicines Agency (EMA), Europe maintains a strong regulatory environment with thousands of authorized medicines and healthcare innovations, supporting continued diagnostic advancements and adoption.

The Middle East and Africa (MEA) region, though the smallest at 0.62 USD Billion in 2024, signifies opportunities for expansion due to increasing awareness of immunodiagnostic applications.This regional breakdown illustrates varied growth trajectories, reflecting distinct healthcare dynamics and investment opportunities across the Global Market.

## Competitive Benchmarking

The Global Immunoassay Market is characterized by its dynamic and competitive landscape, driven by technological advancements, increasing demand for accurate diagnostics, and a rising prevalence of chronic diseases. The competitive insights reflect a diverse range of players engaged in developing innovative immunoassay techniques and products. As the market continues to evolve, key competitors are vying for market share by enhancing their product portfolios and expanding their geographical reach.
 
Companies are increasingly focusing on strategic approaches such as partnerships, collaborations, and mergers to leverage each other's strengths, thereby gaining a competitive edge. The ongoing trend towards automation and the integration of artificial intelligence in diagnostic tools are also influencing market dynamics, contributing to the overall growth and competitive positioning of organizations within the sector.Abbott Laboratories has established a significant presence in the global market, leveraging its extensive experience and robust research and development capabilities.
 
The company is renowned for its innovative diagnostic solutions, offering a wide array of immunoassay products that cater to various therapeutic areas. Abbott's commitment to advancing healthcare solutions is a key strength, as it consistently invests in new technologies and methodologies to improve diagnostic accuracy and efficiency. The company benefits from a strong global distribution network, enabling it to reach a diverse customer base and respond adeptly to regional market needs.
 
Its established brand reputation and robust portfolio of immunoassay systems solidify Abbott Laboratories' position as a leading player in this competitive market. Hologic is another influential player in the global market, recognized for its specialized focus on women's health and infectious diseases. The company offers a variety of innovative immunoassay products, including assays for the detection of sexually transmitted infections and other health conditions.
 
Hologic's strengths lie in its commitment to innovation, with a strong emphasis on research and development that drives product advancement and clinical applications. The company has made significant strides in expanding its market presence through strategic mergers and acquisitions, allowing it to integrate complementary technologies and enhance its service offerings. This proactive approach not only broadens Hologic's product range but also strengthens its competitive position on a global scale, making it a formidable force within the immunoassay sector.

## Recent News & Developments

The Global Immunoassay Market has recently witnessed significant developments, particularly with key players such as Abbott Laboratories, Hologic, and Thermo Fisher Scientific pushing forward innovations in diagnostic tools. Notably, in July 2023, Abbott Laboratories announced the launch of a new immunoassay test designed for early detection of diseases, enhancing its product portfolio. Additionally, Quest Diagnostics is expanding its capabilities with new partnerships aimed at integrating advanced technologies in immunoassays.

Therapeutic drug monitoring market trends suggest rapid growth as the valuation of companies like Merck KGaA and Roche Diagnostics increases, driven by the rising demand for faster and more accurate diagnostic tests amid global health challenges. Furthermore, in a strategic move, Danaher Corporation acquired a smaller biotech firm in August 2023 to bolster its immunoassay capabilities. The [immuno oncology assays](https://www.marketresearchfuture.com/reports/immuno-oncology-assay-market-42957) market has seen strong performance overall, attributed to advancements in Research and Development and increasing end-user adoption across clinical laboratories and hospitals.

In the last two years, significant advancements have been noted, such as the introduction of point-of-care immunoassay devices in May 2022, which have revolutionized diagnostic procedures. Major socioeconomic factors and ongoing healthcare needs continue to influence trends within the global market.

## Report Scope

| MARKET SIZE 2024 | 25.25(USD Billion) |
| --- | --- |
| MARKET SIZE 2025 | 26.22(USD Billion) |
| MARKET SIZE 2035 | 38.3(USD Billion) |
| COMPOUND ANNUAL GROWTH RATE (CAGR) | 3.86% (2025 - 2035) |
| REPORT COVERAGE | Revenue Forecast, Competitive Landscape, Growth Factors, and Trends |
| BASE YEAR | 2024 |
| Market Forecast Period | 2025 - 2035 |
| Historical Data | 2019 - 2024 |
| Market Forecast Units | USD Billion |
| Key Companies Profiled | Abbott Laboratories (US), Roche Diagnostics (CH), Siemens Healthineers (DE), Thermo Fisher Scientific (US), Ortho Clinical Diagnostics (US), Bio-Rad Laboratories (US), Danaher Corporation (US), PerkinElmer (US), Fujirebio (JP) |
| Segments Covered | Types, Technology, Applications, End Use, Regional |
| Key Market Opportunities | Integration of advanced technologies enhances accuracy and efficiency in the market. |
| Key Market Dynamics | Technological advancements and regulatory changes drive innovation and competition in the market. |
| Countries Covered | North America, Europe, APAC, South America, MEA |

## Frequently Asked Questions

**Q: What is the current valuation of the Immunoassay Market as of 2024?**
A: The Immunoassay Market was valued at 25.25 USD Billion in 2024.

**Q: What is the projected market size for the Immunoassay Market by 2035?**
A: The market is projected to reach 38.3 USD Billion by 2035.

**Q: What is the expected CAGR for the Immunoassay Market during the forecast period 2025 - 2035?**
A: The expected CAGR for the Immunoassay Market during 2025 - 2035 is 3.86%.

**Q: Which segment of the Immunoassay Market is expected to grow the most in terms of type?**
A: The Enzyme-Linked Immunosorbent Assay segment is anticipated to grow from 10.5 USD Billion in 2024 to 16.0 USD Billion by 2035.

**Q: How does the Automated Immunoassay segment compare to other technologies in the market?**
A: The Automated Immunoassay segment is projected to increase from 10.0 USD Billion in 2024 to 15.0 USD Billion by 2035, indicating strong growth.

**Q: What applications are driving growth in the Immunoassay Market?**
A: Clinical Diagnostics is expected to expand from 10.5 USD Billion in 2024 to 16.0 USD Billion by 2035, leading the application segments.

**Q: Which end-use segment is likely to see the highest valuation by 2035?**
A: The Hospitals segment is projected to grow from 8.5 USD Billion in 2024 to 12.5 USD Billion by 2035, suggesting robust demand.

**Q: Who are the key players in the Immunoassay Market?**
A: Key players include Abbott Laboratories, Roche Diagnostics, Siemens Healthineers, and Thermo Fisher Scientific, among others.

**Q: What is the expected growth for the Drug Development application in the Immunoassay Market?**
A: The Drug Development application is anticipated to grow from 6.0 USD Billion in 2024 to 9.0 USD Billion by 2035.

**Q: How does the growth of the Immunoassay Market reflect on environmental testing?**
A: The Environmental Testing segment is projected to increase from 4.0 USD Billion in 2024 to 5.5 USD Billion by 2035, indicating a positive trend.


---

*This Markdown endpoint is provided for AI systems and LLM crawlers. For the full interactive report visit https://www.marketresearchfuture.com/reports/immunoassay-market-5841*